Hereditary transthyretin (hATTR) amyloidosis is a rare genetic disease where abnormal TTR protein builds up in nerves and the heart. New RNA-based therapies have transformed outcomes — but early diagnosis is critical.
hATTR affects an estimated 50,000 people worldwide. Most go undiagnosed for years due to overlapping symptoms with common conditions.
🕐 Last updated: March 23, 2026📡 Sources: NIH · CDC · FDA · ClinicalTrials.gov12 articles
🔔
Get hATTR Alerts
Free weekly updates from NIH, CDC & FDA when new research drops. No spam. Unsubscribe anytime.
FDAJanuary 20, 2026
Inotersen and Eplontersen: Antisense Therapies for hATTR Polyneuropathy
Antisense oligonucleotides (ASOs) are a second class of gene-silencing therapy for hATTR, working through RNA degradation at the cellular level rather than the RNAi pathway used by patisiran and vutrisiran. Two ASOs have been developed for hATTR: inotersen (Tegsedi, Ionis/Akcea) and the next-generation eplontersen (Wainua, AstraZeneca/Ionis).
Inotersen was FDA-approved in 2018 for hATTR polyneuropathy based on the NEURO-TTR trial, which showed significant preservation of neurological function vs. placebo at 65 weeks. It's administered as a weekly subcutaneous injection. However, it carries a black box warning for thrombocytopenia (low platelets) and nephrotoxicity — patients require weekly platelet and renal monitoring, particularly in the first year. It is available through a REMS program.
Eplontersen, approved by the FDA in December 2023, is an enhanced-generation ASO conjugated to GalNAc (liver-targeting ligand) allowing monthly subcutaneous dosing versus weekly for inotersen. The CARDIO-TTRansform trial showed a >80% TTR reduction and significantly improved neurological outcomes with a more favorable safety profile than inotersen — no mandatory REMS requirement. Eplontersen is now considered a leading option for patients preferring an injection over IV infusion and where vutrisiran is not the preferred choice.
Specialist Centers for hATTR: How to Find Expert Care
hATTR amyloidosis is rare and complex enough that most patients benefit from being seen at a dedicated amyloidosis center, even if ongoing management happens locally. Amyloidosis specialists — typically neurologists, cardiologists, and hepatologists with specific expertise in the disease — can confirm diagnosis, optimize therapy selection, and provide access to clinical trials.
In the United States, major amyloidosis centers include: Boston University (Dr. John Berk's program), Mayo Clinic (Rochester and Scottsdale), Columbia University Medical Center, Stanford, UCSF, Cleveland Clinic, and the University of Pennsylvania. The Amyloidosis Research Consortium maintains an updated directory at arci.org. Internationally, UK Amyloidosis Centre (Royal Free Hospital, London) and Andrade Disease Center (Portugal) are leading programs.
For patients in areas without amyloidosis specialists, telemedicine consultations are increasingly available. Initial consultation at a specialized center, with subsequent management returned to a local neurologist or cardiologist who follows the specialist's guidance, is a practical model for many patients. When seeking a referral, ask your primary care physician or general neurologist specifically for a specialist with "amyloidosis experience" or "ATTR amyloidosis" — the distinction from general peripheral neuropathy clinics matters.
Caring for someone with hATTR amyloidosis involves managing an unpredictable, progressive disease that affects multiple organ systems simultaneously. The caregiver role evolves as the disease advances — from early-stage support with specialist appointments and medication management, to hands-on assistance with mobility, continence, and cardiac monitoring.
Practical early-stage priorities: help coordinate care across neurology, cardiology, and often gastroenterology. Keep a shared medication log — hATTR therapy requires adherence with no missed doses. Assist in monitoring for new or worsening symptoms (increasing shortness of breath, worsening falls, new GI changes). Support dietary and hydration management given autonomic GI dysfunction.
As disease advances: occupational therapy consultations can adapt the home for fall prevention. A PICC line or port may be required for IV patisiran infusions. Autonomic dysfunction requires careful management of orthostatic hypotension (compression garments, salt/fluid intake, timing of meals). Emotional support is critical — hATTR carries significant psychological burden given its genetic nature (the caregiver may also be at risk) and rapid progression. The Amyloidosis Research Consortium (arci.org) offers patient and caregiver support groups, telehealth connections, and a comprehensive disease management guide.
Specialty Pharmacy and Cost Access for hATTR Therapies
hATTR therapies are among the most expensive drugs in the world. Tafamidis (Vyndamax/Vyndaqel) lists at over $200,000/year. Patisiran (Onpattro) and vutrisiran (Amvuttra) are similarly priced. However, cost should not deter patients from seeking these treatments — multiple access pathways exist.
Medicare coverage: tafamidis is covered under Part D (with prior authorization and often requiring documented ATTR-CM diagnosis by specialist, confirmation of NYHA Class I-III). RNAi therapies are covered under Part B as physician-administered infusions/injections. Out-of-pocket costs vary widely by plan. Medicare Advantage plans may have different prior auth pathways. The Medicare Extra Help program can reduce Part D costs for low-income patients.
Commercial insurance: Alnylam offers patient support programs including co-pay assistance through "myALNYLAM." Pfizer (tafamidis) operates "Pfizer RareConnect" for financial assistance. Both manufacturers have patient access teams who work directly with specialty pharmacies and insurer appeals. For patients who exhaust standard insurance avenues, free drug programs exist through manufacturer compassionate use programs. Work with your specialist's prior authorization team — appeals are often successful with adequate clinical documentation.
hATTR Clinical Trial Landscape 2026: Key Studies to Know
The hATTR treatment pipeline in 2026 is one of the most active in rare disease. Several next-generation therapies and expanded indications are in late-stage development.
Key trials: HELIOS-B confirmed vutrisiran's cardiac benefit — the first RNAi drug to demonstrate a mortality reduction in ATTR cardiomyopathy. Eplontersen (CARDIO-TTRansform, AstraZeneca/Ionis), an antisense oligonucleotide, reported Phase 3 data showing over 80% TTR reduction and significant cardiac stabilization. The APOLLO-B trial continues to generate long-term follow-up data for patisiran in cardiomyopathy. Small molecule stabilizers next-generation (acoramidis, BridgeBio) showed superiority over placebo in the ATTRibute-CM trial with mortality benefit.
Gene therapy approaches (NTLA-2001, Intellia) are in Phase 1/2, with early data showing near-complete and potentially durable TTR silencing from a single infusion — potentially a one-time cure. Combination therapy trials (stabilizer plus silencer) are being designed. Patients interested in trials can search ClinicalTrials.gov under "ATTR amyloidosis" — major enrolling centers include Boston University, Mayo Clinic, Columbia, Stanford, and international centers through the Amyloidosis Research Consortium.
hATTR cardiomyopathy results from amyloid fibril infiltration of the cardiac muscle, causing progressive thickening of the heart walls (hypertrophy), impaired relaxation (diastolic dysfunction), and eventually systolic dysfunction and right heart failure. It's a form of restrictive cardiomyopathy often confused with hypertensive heart disease or hypertrophic cardiomyopathy.
The key diagnostic clues: ECG showing low voltage despite echocardiographic evidence of significant wall thickening (the classic "discordant" pattern), a granular or sparkling texture on echo, and markedly elevated BNP/NTproBNP and troponin T. Cardiac MRI with late gadolinium enhancement confirms diffuse subendocardial or transmural amyloid deposition. Technetium-pyrophosphate (99mTc-PYP) scintigraphy is a non-biopsy diagnostic tool with high specificity for ATTR cardiomyopathy when serum protein markers are negative.
Monitoring frequency depends on disease stage: at minimum, echocardiography, ECG, and biomarkers every 6 months. Holter monitoring is warranted given the high incidence of arrhythmia and AV conduction block. As right ventricular function declines, referral to an advanced heart failure program should be considered for evaluation of ICD implantation, cardiac resynchronization therapy, and ultimately heart transplant listing.
hATTR polyneuropathy typically begins with a length-dependent sensorimotor neuropathy — meaning it starts in the feet and hands and gradually ascends. Early symptoms include numbness, tingling, burning pain, and reduced pain/temperature sensation in the feet. As the disease progresses, motor weakness develops, affecting gait and hand function.
Autonomic neuropathy is a particularly distinctive feature of hATTR and often precedes or accompanies sensorimotor symptoms. It manifests as orthostatic hypotension (dizziness on standing), irregular bowel function (alternating constipation and diarrhea), erectile dysfunction, urinary dysfunction, and sweating abnormalities. These symptoms are frequently misattributed to other causes, delaying diagnosis.
Carpal tunnel syndrome is an underappreciated early red flag. hATTR patients commonly develop bilateral carpal tunnel syndrome years before a formal diagnosis — and in retrospect, many have had amyloid deposits in the carpal tunnel ligament. Any patient with bilateral CTS plus peripheral neuropathy, heart failure, or autonomic dysfunction should be evaluated for ATTR amyloidosis. The nM-NIS+7 score is used in clinical practice and trials to quantify neuropathic burden over time.
Genetic Testing for hATTR: Who Should Be Tested and Why
hATTR amyloidosis is an autosomal dominant condition, meaning each child of an affected parent has a 50% chance of inheriting the disease-causing mutation. Cascade genetic testing of first-degree relatives — parents, siblings, and children — is the standard recommendation after an index case is identified.
Testing is done by sequencing the TTR gene from a blood sample. Commercial testing typically costs $200–$500 and is covered by most major insurers after diagnosis of a first-degree relative. Genetic counselors play a critical role in interpreting results, explaining penetrance (not all carriers develop disease), discussing testing of minors, and addressing the emotional impact of a positive result.
Presymptomatic testing allows for early surveillance and — crucially — early treatment initiation before irreversible organ damage occurs. Guidelines recommend that carriers begin regular monitoring with echocardiogram, ECG, nerve conduction studies, and serum biomarkers (BNP, NTproBNP, troponin) even before symptom onset. Therapies are far more effective when started early in disease course.
The TTR Gene: Understanding Hereditary Amyloidosis Mutations
The transthyretin (TTR) gene, located on chromosome 18, encodes the TTR protein — a tetrameric transport protein produced mainly by the liver. In hATTR, a single-letter change in one copy of the TTR gene (autosomal dominant inheritance) is enough to cause disease because mutant and normal TTR subunits can co-assemble into unstable mixed tetramers that misfold and deposit as amyloid.
Over 120 disease-causing TTR mutations have been documented. Three are particularly common in the US: Val30Met (originally Portuguese, Swedish, Japanese ancestry; the "classic" hereditary variant), Val122Ile (West African descent; primarily cardiac presentation), and Thr60Ala (Irish ancestry; mixed cardiac and neuropathic). The Glu89Gln and Asp38Ala mutations are associated with leptomeningeal amyloidosis, a CNS variant.
Penetrance is variable — even carriers of the same mutation may have very different ages of onset and rates of progression. Environmental and genetic modifiers, including other TTR variants and complement of normal TTR expression, influence disease course. Understanding your specific mutation helps predict which organs are at highest risk and informs surveillance strategy.
Tafamidis for Cardiac hATTR: Who Qualifies and What to Expect
Tafamidis (Vyndaqel, Vyndamax) is the first FDA-approved therapy specifically for ATTR cardiomyopathy — covering both hereditary (hATTR) and wild-type forms. Approved in 2019, it works through a completely different mechanism than RNAi drugs: tafamidis stabilizes the TTR tetramer, preventing it from unfolding and forming amyloid fibrils in the first place.
The ATTR-ACT trial enrolled 441 patients and showed tafamidis reduced all-cause mortality by 30% and cardiovascular hospitalizations by 32% over 30 months versus placebo. Functional decline and quality of life were significantly better preserved. These are landmark outcomes for a disease that previously had no approved cardiac treatment.
Tafamidis comes in two formulations: Vyndaqel (20 mg tafamidis meglumine, 4 capsules daily) and Vyndamax (61 mg tafamidis free acid, 1 capsule daily — bioequivalent). Vyndamax is generally preferred for its single-pill convenience. The major barrier: list price exceeds $200,000/year. Medicare covers it with prior auth and Step Therapy requirements in many Part D plans. Manufacturer assistance programs exist for commercial insurance patients. A specialist referral is required; general cardiologists may need to partner with amyloidosis centers for diagnosis confirmation before prescribing.
Patisiran vs Vutrisiran: Comparing the Two Approved RNAi Therapies for hATTR
Two RNA interference (RNAi) drugs are FDA-approved for hATTR polyneuropathy: patisiran (Onpattro, Alnylam) and vutrisiran (Amvuttra, Alnylam). Both work by silencing TTR gene expression in the liver, dramatically reducing circulating mutant TTR protein and halting fibril deposition.
Patisiran was approved in 2018 and is administered as an IV infusion every 3 weeks. Vutrisiran arrived in 2022 as a once-quarterly subcutaneous injection — a significant convenience improvement. The HELIOS-A trial showed vutrisiran reduced modified NIS+7 neurological impairment scores by 49% vs. a 68% reduction for the landmark APOLLO patisiran trial (different populations), and both demonstrated meaningful preservation of quality of life and walking ability.
The key practical differences: vutrisiran's quarterly injection is easier to manage than patisiran's 80-minute IV infusion, and vutrisiran does not require pre-medication with steroids and antihistamines. Both are covered under Medicare Part B with prior authorization. Cardiomyopathy benefit was demonstrated for vutrisiran in HELIOS-B; patisiran's cardiac data remains exploratory. Choice between them is typically made with your specialist based on disease severity, cardiac involvement, and infusion center access.
What Is hATTR Amyloidosis? Understanding Your Diagnosis
Hereditary transthyretin (hATTR) amyloidosis is a rare, progressive genetic disease caused by mutations in the TTR gene. The TTR protein — produced mainly by the liver — normally forms a stable tetramer that transports thyroxine and retinol. In hATTR, TTR misfolds and aggregates into insoluble amyloid fibrils that deposit in nerves, the heart, the kidneys, and other organs.
There are two main forms: hATTR polyneuropathy (nerve damage, numbness, weakness, GI dysfunction) and hATTR cardiomyopathy (thickened heart walls, heart failure, arrhythmia). Many patients have mixed involvement affecting both nerves and the heart. Symptoms typically begin in the 30s–60s depending on the specific mutation.
Over 120 TTR mutations have been identified worldwide. The V30M mutation is the most common globally, while Val122Ile is prevalent in people of West African descent and affects an estimated 1.3 million African Americans. The average time from symptom onset to diagnosis is 4–5 years due to the disease's overlap with common conditions like carpal tunnel syndrome, polyneuropathy, or heart failure.
My Sugar Pill may earn a commission when you book — at no extra cost to you. One way we keep My Sugar Pill free.
About this content
Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries are written in plain English. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.
About My Sugar Pill · No sponsored content · No data selling · Free, always.